| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections.
|
Nat Med
|
2002
|
10.03
|
|
2
|
The end of AIDS: HIV infection as a chronic disease.
|
Lancet
|
2013
|
3.96
|
|
3
|
Effect of treatment, during primary infection, on establishment and clearance of cellular reservoirs of HIV-1.
|
J Infect Dis
|
2005
|
3.93
|
|
4
|
Differences in HIV burden and immune activation within the gut of HIV-positive patients receiving suppressive antiretroviral therapy.
|
J Infect Dis
|
2010
|
2.98
|
|
5
|
Effect of raltegravir-containing intensification on HIV burden and T-cell activation in multiple gut sites of HIV-positive adults on suppressive antiretroviral therapy.
|
AIDS
|
2010
|
2.94
|
|
6
|
Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment.
|
AIDS
|
2009
|
2.91
|
|
7
|
Intensive care of patients with HIV infection.
|
N Engl J Med
|
2006
|
2.86
|
|
8
|
The case for earlier treatment of HIV infection.
|
Clin Infect Dis
|
2004
|
2.20
|
|
9
|
The effect of expanded antiretroviral treatment strategies on the HIV epidemic among men who have sex with men in San Francisco.
|
Clin Infect Dis
|
2011
|
2.20
|
|
10
|
Identifying locations of recent TB transmission in rural Uganda: a multidisciplinary approach.
|
Trop Med Int Health
|
2015
|
2.10
|
|
11
|
Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170.
|
J Infect Dis
|
2007
|
2.05
|
|
12
|
Comparison of an interferon-gamma release assay with tuberculin skin testing in HIV-infected individuals.
|
Am J Respir Crit Care Med
|
2007
|
2.00
|
|
13
|
Antimalarial activity of human immunodeficiency virus type 1 protease inhibitors.
|
Antimicrob Agents Chemother
|
2005
|
2.00
|
|
14
|
Neurocognitive and motor deficits in HIV-infected Ugandan children with high CD4 cell counts.
|
Clin Infect Dis
|
2012
|
1.97
|
|
15
|
Leveraging rapid community-based HIV testing campaigns for non-communicable diseases in rural Uganda.
|
PLoS One
|
2012
|
1.77
|
|
16
|
Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy.
|
Clin Infect Dis
|
2008
|
1.66
|
|
17
|
Sudden cardiac death in patients with human immunodeficiency virus infection.
|
J Am Coll Cardiol
|
2012
|
1.44
|
|
18
|
The distribution of HIV DNA and RNA in cell subsets differs in gut and blood of HIV-positive patients on ART: implications for viral persistence.
|
J Infect Dis
|
2013
|
1.39
|
|
19
|
Reducing deaths from tuberculosis in antiretroviral treatment programmes in sub-Saharan Africa.
|
AIDS
|
2012
|
1.26
|
|
20
|
Assessment of population-based HIV RNA levels in a rural east African setting using a fingerprick-based blood collection method.
|
Clin Infect Dis
|
2012
|
1.26
|
|
21
|
Treatment strategies for HIV-infected patients with tuberculosis: ongoing and planned clinical trials.
|
J Infect Dis
|
2007
|
1.24
|
|
22
|
HIV and tuberculosis--science and implementation to turn the tide and reduce deaths.
|
J Int AIDS Soc
|
2012
|
1.21
|
|
23
|
Baseline predictors of CD4 T-lymphocyte recovery with combination antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2002
|
1.21
|
|
24
|
HIV-subtype A is associated with poorer neuropsychological performance compared with subtype D in antiretroviral therapy-naive Ugandan children.
|
AIDS
|
2010
|
1.16
|
|
25
|
Tuberculosis immune reconstitution inflammatory syndrome in A5221 STRIDE: timing, severity, and implications for HIV-TB programs.
|
J Acquir Immune Defic Syndr
|
2014
|
1.14
|
|
26
|
Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.
|
Clin Infect Dis
|
2013
|
1.11
|
|
27
|
"A bird in the hand...": a commentary on the test and treat approach for HIV.
|
Arch Intern Med
|
2010
|
1.08
|
|
28
|
The effect of a "universal antiretroviral therapy" recommendation on HIV RNA levels among HIV-infected patients entering care with a CD4 count greater than 500/μL in a public health setting.
|
Clin Infect Dis
|
2012
|
1.06
|
|
29
|
Hair and plasma data show that lopinavir, ritonavir, and efavirenz all transfer from mother to infant in utero, but only efavirenz transfers via breastfeeding.
|
J Acquir Immune Defic Syndr
|
2013
|
1.05
|
|
30
|
Tuberculosis as part of the natural history of HIV infection in developing countries.
|
Clin Infect Dis
|
2010
|
1.05
|
|
31
|
Early virologic failure and the development of antiretroviral drug resistance mutations in HIV-infected Ugandan children.
|
J Acquir Immune Defic Syndr
|
2011
|
1.04
|
|
32
|
Successful antiretroviral therapy delivery and retention in care among asymptomatic individuals with high CD4+ T-cell counts above 350 cells/μl in rural Uganda.
|
AIDS
|
2014
|
1.03
|
|
33
|
Tuberculosis treatment in HIV infected Ugandans with CD4 counts>350 cells/mm reduces immune activation with no effect on HIV load or CD4 count.
|
PLoS One
|
2010
|
0.99
|
|
34
|
Sex differences in HIV RNA level and CD4 cell percentage during childhood.
|
Clin Infect Dis
|
2011
|
0.99
|
|
35
|
Improved employment and education outcomes in households of HIV-infected adults with high CD4 cell counts: evidence from a community health campaign in Uganda.
|
AIDS
|
2013
|
0.99
|
|
36
|
High retention in care among HIV-infected patients entering care with CD4 levels >350 cells/μL under routine program conditions in Uganda.
|
Clin Infect Dis
|
2013
|
0.98
|
|
37
|
A comparison of methods for measuring rectal HIV levels suggests that HIV DNA resides in cells other than CD4+ T cells, including myeloid cells.
|
AIDS
|
2014
|
0.98
|
|
38
|
Efficacy and safety of lopinavir/ritonavir versus efavirenz-based antiretroviral therapy in HIV-infected pregnant Ugandan women.
|
AIDS
|
2015
|
0.97
|
|
39
|
Evaluation of two line probe assays for rapid detection of Mycobacterium tuberculosis, tuberculosis (TB) drug resistance, and non-TB Mycobacteria in HIV-infected individuals with suspected TB.
|
J Clin Microbiol
|
2014
|
0.95
|
|
40
|
Efficacy and safety of three regimens for the prevention of malaria in young HIV-exposed Ugandan children: a randomized controlled trial.
|
AIDS
|
2014
|
0.95
|
|
41
|
Hair concentrations of antiretrovirals predict viral suppression in HIV-infected pregnant and breastfeeding Ugandan women.
|
AIDS
|
2015
|
0.94
|
|
42
|
Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection.
|
AIDS
|
2011
|
0.92
|
|
43
|
Nontuberculous mycobacteria in the HIV infected patient.
|
Clin Chest Med
|
2002
|
0.92
|
|
44
|
Changes in population HIV RNA levels in Mbarara, Uganda, during scale-up of HIV antiretroviral therapy access.
|
J Acquir Immune Defic Syndr
|
2014
|
0.92
|
|
45
|
Polymerase chain reaction of secA1 on sputum or oral wash samples for the diagnosis of pulmonary tuberculosis.
|
Clin Infect Dis
|
2009
|
0.91
|
|
46
|
Evaluating linkage to care for hypertension after community-based screening in rural Uganda.
|
Trop Med Int Health
|
2014
|
0.91
|
|
47
|
Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda.
|
AIDS
|
2007
|
0.91
|
|
48
|
HIV integrase inhibitors--out of the pipeline and into the clinic.
|
N Engl J Med
|
2008
|
0.90
|
|
49
|
Novel application of Locked Nucleic Acid chemistry for a Taqman assay for measuring diverse human immunodeficiency virus type 1 subtypes.
|
J Virol Methods
|
2010
|
0.89
|
|
50
|
Persistent HIV-1-specific cellular responses despite prolonged therapeutic viral suppression.
|
AIDS
|
2002
|
0.89
|
|
51
|
Complications of HIV disease and antiretroviral therapy.
|
Top HIV Med
|
2009
|
0.88
|
|
52
|
Modification of the Abbott RealTime assay for detection of HIV-1 plasma RNA viral loads less than one copy per milliliter.
|
J Virol Methods
|
2011
|
0.88
|
|
53
|
A randomized trial of treatment interruption before optimized antiretroviral therapy for persons with drug-resistant HIV: 48-week virologic results of ACTG A5086.
|
J Infect Dis
|
2006
|
0.88
|
|
54
|
Overcoming the human immunodeficiency virus obstacle course.
|
JAMA Intern Med
|
2013
|
0.87
|
|
55
|
Risk factors for preterm birth among HIV-infected pregnant Ugandan women randomized to lopinavir/ritonavir- or efavirenz-based antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2014
|
0.87
|
|
56
|
Mycobacterium tuberculosis microbiologic and clinical treatment outcomes in a randomized trial of immediate versus CD4(+)-initiated antiretroviral therapy in HIV-infected adults with a high CD4(+) cell count.
|
Clin Infect Dis
|
2010
|
0.87
|
|
57
|
Short-term risk of HIV disease progression and death in Ugandan children not eligible for antiretroviral therapy.
|
J Acquir Immune Defic Syndr
|
2010
|
0.86
|
|
58
|
High-dose lopinavir/ritonavir in highly treatment-experienced HIV-1 patients: efficacy, safety, and predictors of response.
|
HIV Clin Trials
|
2007
|
0.85
|
|
59
|
Mortality among antiretroviral-eligible patients in an urban public clinic.
|
J Acquir Immune Defic Syndr
|
2011
|
0.85
|
|
60
|
HIV RNA suppression among HIV-infected Ugandan children with measles.
|
J Acquir Immune Defic Syndr
|
2008
|
0.85
|
|
61
|
Antiretroviral therapy and TB.
|
Trop Doct
|
2006
|
0.84
|
|
62
|
High levels of retention in care with streamlined care and universal test and treat in East Africa.
|
AIDS
|
2016
|
0.84
|
|
63
|
Increased adolescent HIV testing with a hybrid mobile strategy in Uganda and Kenya.
|
AIDS
|
2016
|
0.84
|
|
64
|
Implementation and Operational Research: Cost and Efficiency of a Hybrid Mobile Multidisease Testing Approach With High HIV Testing Coverage in East Africa.
|
J Acquir Immune Defic Syndr
|
2016
|
0.83
|
|
65
|
Unexpected low-level viremia among HIV-infected Ugandan adults with untreated active tuberculosis.
|
J Acquir Immune Defic Syndr
|
2008
|
0.83
|
|
66
|
The Effect of Same-Day Observed Initiation of Antiretroviral Therapy on HIV Viral Load and Treatment Outcomes in a US Public Health Setting.
|
J Acquir Immune Defic Syndr
|
2017
|
0.83
|
|
67
|
Complications of HIV disease and antiretroviral therapy.
|
Top HIV Med
|
2005
|
0.82
|
|
68
|
Responding to organ failure in HIV-infected patients.
|
N Engl J Med
|
2003
|
0.82
|
|
69
|
Complications of HIV disease and antiretroviral therapy.
|
Top Antivir Med
|
2011
|
0.81
|
|
70
|
Rapid increase in tuberculosis incidence soon after infection with HIV--a new twist in the twin epidemics.
|
J Infect Dis
|
2004
|
0.81
|
|
71
|
Acceptability and feasibility of serial HIV antibody testing during pregnancy/postpartum and male partner testing in Tororo, Uganda.
|
AIDS Care
|
2013
|
0.81
|
|
72
|
The effect of AIDS Clinical Trials Group Protocol 5164 on the time from Pneumocystis jirovecii pneumonia diagnosis to antiretroviral initiation in routine clinical practice: a case study of diffusion, dissemination, and implementation.
|
Clin Infect Dis
|
2011
|
0.81
|
|
73
|
Household food insecurity, maternal nutritional status, and infant feeding practices among HIV-infected Ugandan women receiving combination antiretroviral therapy.
|
Matern Child Health J
|
2014
|
0.81
|
|
74
|
Changes in the timing of antiretroviral therapy initiation in HIV-infected patients with tuberculosis in Uganda: a study of the diffusion of evidence into practice in the global response to HIV/AIDS.
|
Clin Infect Dis
|
2013
|
0.80
|
|
75
|
Brief Report: Food Insufficiency Is Associated With Lack of Sustained Viral Suppression Among HIV-Infected Pregnant and Breastfeeding Ugandan Women.
|
J Acquir Immune Defic Syndr
|
2016
|
0.79
|
|
76
|
Complications of HIV disease and antiretroviral therapy.
|
Top Antivir Med
|
2012
|
0.79
|
|
77
|
Neonatal mortality in HIV-exposed infants born to women receiving combination antiretroviral therapy in Rural Uganda.
|
J Trop Pediatr
|
2013
|
0.79
|
|
78
|
Complications of HIV disease and antiretroviral treatment.
|
Top HIV Med
|
2010
|
0.78
|
|
79
|
CROI 2013: Complications of HIV disease, viral hepatitis, and antiretroviral therapy.
|
Top Antivir Med
|
2013
|
0.78
|
|
80
|
Tuberculosis drug development: ensuring people living with HIV are not left behind.
|
Am J Respir Crit Care Med
|
2011
|
0.78
|
|
81
|
Tuberculosis Infection in Early Childhood and the Association with HIV-exposure in HIV-uninfected Children in Rural Uganda.
|
Pediatr Infect Dis J
|
2016
|
0.77
|
|
82
|
Complications of HIV disease and antiretroviral therapy. Highlights of the 11th Conference on Retroviruses and Opportunistic Infections, February 8-11, 2004, San Francisco, California, USA.
|
Top HIV Med
|
2004
|
0.76
|
|
83
|
PR Interval and sudden cardiac death in patients with HIV infection.
|
J Infect Dis
|
2012
|
0.75
|
|
84
|
Viral Suppression and Retention in Care up to 5 Years after Initiation of Lifelong ART during Pregnancy (Option B+) in Rural Uganda.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
85
|
Resistance patterns and response to entecavir intensification among HIV-HBV-coinfected adults with persistent HBV viremia.
|
J Acquir Immune Defic Syndr
|
2011
|
0.75
|
|
86
|
Complications of HIV disease and therapy.
|
Top HIV Med
|
2007
|
0.75
|
|
87
|
Isoniazid Preventive Therapy Completion in the Era of Differentiated HIV Care.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
88
|
Predictors of retention in HIV care among youth (15-24) in a universal test-and-treat setting in rural Kenya.
|
J Acquir Immune Defic Syndr
|
2017
|
0.75
|
|
89
|
Cost and efficiency of a hybrid mobile multi-disease testing approach with high HIV testing coverage in East Africa.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|
|
90
|
Highlights of the 15th Conference on Retroviruses and Opportunistic Infections. Complications of HIV disease and therapy.
|
Top HIV Med
|
2008
|
0.75
|
|
91
|
Implementation and Operational Research: Population-Based Active Tuberculosis Case Finding During Large-Scale Mobile HIV Testing Campaigns in Rural Uganda.
|
J Acquir Immune Defic Syndr
|
2016
|
0.75
|